Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Winship Cancer Institute of Emory University, Atlanta, Georgia, United States

Norton Healthcare, Inc., Louisville, Kentucky, United States

Nebraska Cancer Institute, Omaha, Nebraska, United States

Mount Sinai, The Tisch Cancer Instutute, New York, New York, United States

MD Anderson Cancer Center, Houston, Texas, United States

Charité - Campus Benjamin Franklin Med. Klinik m.S. Hämatologie, Onkologie, Berlin, Germany

Klinikum Chemnitz gGmbH, Klinik f. Innere Medizin III, Chemnitz, Germany

Universitätsklinikum Köln, Cologne, Germany

Asklepios Klinik Altona, Haematologie und internistische Onkologie, Hamburg, Germany

Universitätsklinikum Heidelberg, Heidelberg, Germany

Universitätsklinikum Schleswig-Holstein, Kiel, Germany

UKSH Campus Lübeck Klinik für Hämatologie und Onkologie, Lübeck, Germany

Universitätsklinikum Mainz, Mainz, Germany

Semmelweis University, Belgyogyaszati es Onkologiai Klinika, Budapest, Hungary

National Institute of Oncology, Department of Oncological Internal Medicine, Budapest, Hungary

Pécsi Tudományegyetem Klinikai Központ, Pécs, Hungary

Pratia Onkologia Katowice, Katowice, Poland

Pratia Onkologia Kraków, Krakow, Poland

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi, Lodz, Poland

Szpital Wojewodzki w Opolu, Opole, Poland

AIDPORT Sp. zo.o., Skórzewo, Poland

MICS Centrum Medyczne Torun, Torun, Poland

Arensia Clinics SRL, Bucharest, Romania

Oncology Institute Prof. Dr. Ion Chiricuta I.O.C.N., Cluj-Napoca, Romania